

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad - 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



13th November, 2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

Sub: Submission of Un-audited Financial Results for the Quarter ended on 30th September, 2021

We refer to our letter dated 21st October, 2021 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 30th September, 2021.

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 30th September, 2021 along with Limited Review Report thereon.

This is as per Regulation - 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

For ADLINE CHEM LAB LIMITED
(Formerly known as Kamron Laboratories Limited)

FOR, ADLINE CHEM LAB LIMITED
(Formerly Known As Kamron Laboratories Ltd.)

KAMLESH J. LASKARI
MANAGING DIRECTOR 
(DIN: 00461198) **MANAGING DIRECTOR**

Encl: As above.

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.com Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2021

(Rs. In lakh)

Particulars	Quarter ended			Half Year ended (Cumulative)		Previous Year ended 31-03-2021
	30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from operations	0.09	63.14	125.93	63.23	262.14	632.52
2 Other income	15.94	0.00	0.12	15.94	0.12	0.33
3 Total Income (1+2)	16.03	63.14	126.05	79.17	262.26	633.15
4 Expenses						
a. Cost of Materials consumed		-	-		-	-
b. Purchases of stock-in-trade	(0.3)	32.14	20.32	31.84	78.52	233.26
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.2	13.08	22.32	13.28	35.94	69.96
d. Employee benefits expense	8.65	6.25	44.00	14.90	72.56	171.43
e. Finance costs	-	0.44	0.41	0.44	0.65	3.27
f. Depreciation & amortisation expense	25.59	25.58	28.71	51.17	57.37	102.34
g. Other expenses	9.18	13.72	44.65	22.90	77.62	181.22
Total Expenses	43.32	91.21	160.41	134.53	322.66	761.48
5 Profit / (Loss) before exceptional items and tax (3-4)	(27.29)	(28.07)	(34.36)	(55.36)	(60.40)	(128.33)
6 Exceptional items	-	-	-	-	-	-
7 Profit / (Loss) before tax (5+6)	(27.29)	(28.07)	(34.36)	(55.36)	(60.40)	(128.33)
8 Tax expense:						
Current tax	-	-	-	-	-	-
Deferred tax	-	-	-	-	-	-
9 Profit/ (Loss) for the period from continuing operations (7-8)	(27.29)	(28.07)	(34.36)	(55.36)	(60.40)	(128.33)
10 Profit/ (loss) from discontinuing operations before Tax	-	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-	-
12 Profit/ (loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13 Profit/ (Loss) for the period (9+12)	(27.29)	(28.07)	(34.36)	(55.36)	(60.40)	(128.33)



Kamruni Lata

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.com Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



Particulars	Quarter ended			Half Year ended (Cumulative)		Previous Year ended 31-03-2021
	30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
14 Other Comprehensive Income						
<i>Items that will not be reclassified subsequently to profit or loss</i>	-	-	-	-	-	-
Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
<i>Items that will be reclassified subsequently to profit or loss</i>	-	-	-	-	-	-
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Other Comprehensive Income, net of tax	-	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14)	(27.29)	(28.07)	(34.36)	(55.36)	(60.40)	(128.33)
16 Paid-up equity shares capital (Face Value per share Rs. 10/-)	585.00	585.00	585.00	585.00	585.00	585.00
17 Reserves excluding Revaluation Reserves						
18 Earnings Per Share of Rs.10/- each (for continuing operations)						
- Basic	(0.47)	(0.48)	(0.59)	(0.95)	(1.03)	(2.19)
- Diluted	(0.47)	(0.48)	(0.59)	(0.95)	(1.03)	(2.19)
19 Earnings Per Share of Rs.10/- each (for discontinued operations)						
- Basic	-	-	-	-	-	-
- Diluted	-	-	-	-	-	-
20 Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
- Basic	(0.47)	(0.48)	(0.59)	(0.95)	(1.03)	(2.19)
- Diluted	(0.47)	(0.48)	(0.59)	(0.95)	(1.03)	(2.19)



Santhosh / Lakshmi

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.com Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



1. STATEMENT OF STANDALONE ASSETS AND LIABILITIES

(Rs. In lakh)

Sr. No.	Particulars	As at 30-09-2021 (Unaudited)	As at 31-03-2021 (Audited)
	ASSETS		
1	Non-Current Assets		
	Property, plant and equipment	0.00	0.00
	Capital work-in-progress	-	-
	Investment property	-	-
	Goodwill	-	-
	Other intangible Assets	312.96	364.13
	Intangible Assets under development	-	-
	Biological Assets other than bearer plants	-	-
	Non-Current Financial Assets:	-	-
	(i) Investments, Non-Current	-	-
	(ii) Trade receivables, Non-Current	-	-
	(iii) Loans, Non-Current	0.97	0.90
	Deferred tax Assets (net)	-	-
	Other Non-Current Assets	-	-
	Total Non-Current Assets	313.93	365.03
2	Current Assets		
	Inventories	25.94	39.22
	Current financial asset:		
	(i) Current investments	-	-
	(ii) Trade receivables, Current	34.03	158.28
	(iii) Cash and cash equivalents	4.44	(15.71)
	(iv) Bank balance other than above	-	-
	(v) Loans, Current	5.45	6.12
	(vi) Other Current financial Assets	-	-
	Current tax Assets (net)	-	-
	Other Current Assets	10.86	10.43
	Total Current Assets	80.72	198.34
3	Non-current assets classified as held for sale	-	-
4	Regulatory deferral account debit balances and related deferred tax Assets	-	-
	TOTAL ASSETS	394.65	563.37



Kamruni Karan

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.com Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



EQUITY AND LIABILITIES		
1	Equity	
	Equity share capital	585
	Other Equity	(447.31)
	Total equity attributable to owners of parent	137.69
	Non-controlling Interest	-
	Total Equity	137.69
2	Liabilities	
	Non-Current Liabilities	
	Non-Current financial Liabilities:	
	(i) Borrowings, Non-Current	-
	(ii) Trade payables, Non-Current	-
	(a) total outstanding dues of micro enterprises and small enterprises	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	-
	(iii) Other Non-Current financial Liabilities	-
	Provisions, Non-Current	33.86
	Deferred tax Liabilities (net)	4.58
	Deferred government grants, Non-current	-
	Other Non-Current Liabilities	-
	Total Non-Current Liabilities	38.44
	Current Liabilities	
	Current financial Liabilities:	
	(i) Borrowings, Current	167.28
	(ii) Trade payables, Current	
	(a) total outstanding dues of micro enterprises and small enterprises	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	9.95
	(iii) Other Current financial Liabilities	-
	Other Current Liabilities	16.29
	Provisions, Current	25.00
	Current tax Liabilities (Net)	-
	Deferred government grants, Current	-
	Total Current Liabilities	218.52
3	Liabilities directly associated with assets in disposal group classified as held for sale	-
4	Regulatory deferral account credit balances and related deferred tax liability	-
	Total Liabilities	256.96
	TOTAL EQUITY AND LIABILITIES	394.65



Kamron Labs

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.com Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



2. Statement of Unaudited Cash Flows for the period ended 30th September, 2021

(Rs. in Lakh)

	Year ended 30 th Sept,2021	Year ended 31 st March,2021
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit(Loss) after tax	-55.36634	-128.3358
Adjustments for finance costs	0	0
Depreciation/ amortization	51.17154	102.34308
Profit on sale/ write off of fixed assets(net)	0	-0.06307
Interest expense	0.43985	3.27101
Interest income	-0.00002	-0.00015
Operating profit before working capital changes		
Sub Total A	-3.75497	-22.78493
(Increase)/ decrease in trade receivables	124.25319	-15.20865
(Increase)/ decrease in inventories	13.28067	69.95754
(Increase)/ decrease in loans and advances	0.1671	5.38739
Increase/ (decrease)in trade and other payables	-113.35308	-66.76822
Sub Total B	24.34788	-6.63194
Cash generated from operations		
Direct taxes and fringe benefit tax paid	0	0
Net cash generated from operating activities-I (A+B)	20.59291	-29.41687
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets	0	0
Sale proceeds from assets	0	-1.15098
Profit on Sales of assets	0	12.89997
Interest income	0.00002	0.00015
Net cash (used in) investing activities -II		
Sub Total C	0.00002	11.74914
CASH FLOW FROM OPERATING AND INVESTING ACTIVITIES-III (I+II) (A+B+C)	20.59293	-17.66773
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayments of other borrowings	0	0
Proceeds/(repayments) of other borrowings (net)	0	0
Interest expense	-0.43985	-3.27101
Net cash (used in)/ from financing activities		
Sub Total D	-0.43985	-2.02242
Net increase/(decrease)in cash and cash equivalents (III+D)	20.15308	-20.93874
Cash and cash equivalents at the beginning of the year	-15.71233	5.22641
Cash and cash equivalents at the end of the year	4.4407496	-15.71233



(Signature)

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad - 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.com Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



Notes:

3	The Company is operating only in one segment i.e. Pharmaceuticals Products. Hence segment reporting is not given.
4	The Company is associated with Centis Lifecare Private Limited and Kamron Healthcare Private Limited.
5	Provision for taxation/deferred taxation, if any, will be made at the year end.
6	Figures, wherever required, are regrouped/ rearranged.
6	The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 13 th November, 2021.
7	The financial results are prepared in accordance with the Indian Accounting Standards ("Ind AS"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, and the Companies (Indian Accounting Standards) (Amendment) Rules, 2016.
8	The name of the Company has been changed to "Adline Chem Lab Limited" from "Kamron Laboratories Limited" w.e.f. 13 th October, 2021.

For ADLINE CHEM LAB LIMITED

(Formerly known as Kamron Laboratories Limited)

FOR, ADLINE CHEM LAB LIMITED

(Formerly Known As Kamron Laboratories Ltd.)

Date: 13th November, 2021.

Place: Ahmedabad

Kamlesh J. Laskari
MANAGING DIRECTOR

KAMLESH J. LASKARI
MANAGING DIRECTOR

(DIN: 00461198)

LIMITED REVIEW REPORT

Review Report to the Board of Directors of Adline Chem Lab Limited


We have reviewed the accompanying statement of unaudited standalone financial results of Adline Chem Lab Limited for the period ended 30th Sept 2021, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations"). The company was formerly known as Kamron Laboratories Ltd and the Registrar of companies Ahmedabad has generated on 13th October 2021 Certification of incorporation pursuant to change of name.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Rangwala & Co.
Chartered Accountants
(Firm's Registration No. 115833W)



(A.K. TIMBAWALA)
Partner
(Membership No. 180746)
(UDIN: 21180746AAAABD6220)

Place: Ahmedabad.
Date: 13-11-2021.

LIMITED REVIEW REPORT

Review Report to the Board of Directors of Adline Chem Lab Limited


We have reviewed the accompanying statement of unaudited standalone financial results of Adline Chem Lab Limited for the period ended 30th Sept 2021, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations"). The company was formerly known as Kamron Laboratories Ltd and the Registrar of companies Ahmedabad has generated on 13th October 2021 Certification of incorporation pursuant to change of name.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Rangwala & Co.
Chartered Accountants
(Firm's Registration No. 115833W)




(A.K. TIMBAWALA)

Partner

(Membership No. 180746)

(UDIN: 21180746AAAABD6220)



Place: Ahmedabad.

Date: 13-11-2021.